Physician profile
Charles S Pewitt
NPI 1740389980
$22,593.19
in general payments reported to CMS, 2019-2025
55 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,182 · 2020: $3,060 · 2021: $3,964 · 2022: $3,883 · 2023: $3,312 · 2024: $2,452 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,484 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,483.92 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,924.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,282.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,352.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,224.21 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,160.02 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $1,055.80 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $973.92 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $857.69 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $807.39 | 2019-2024 | |
| Pfizer INC. | $712.86 | 2019-2025 | |
| Esperion Therapeutics, INC. | $584.27 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $571.65 | 2019-2025 | Xifaxan |
| Allergan, INC. | $521.48 | 2019-2020 | |
| Amarin Pharma, INC. | $504.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $412.79 | 2022-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.